IVA
Inventiva S.A.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Inventiva S.A.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
No thesis.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
No peers for Inventiva S.A. yet.
No peers for Inventiva S.A. yet.
Annual filing, covered
20-F parsed · Apr 8 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Apr 8 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Inventiva S.A.
3.66
| Manager | Value | % base | |
|---|---|---|---|
| Caligan Partners | $30.9M | 9.66% | +64.09% |
| Samsara BioCapital | $23.9M | 7.47% | +21.56% |
| Paradigm Biocapital | $15.1M | 4.73% | 0.00% |
| Andera Partners | $13.7M | 4.30% | +99.83% |
| ADAR1 | $13.6M | 4.27% | +65.87% |
| Manager | Value | % base | |
|---|---|---|---|
| Caligan Partners | $30.9M | 9.66% | +64.09% |
| Samsara BioCapital | $23.9M | 7.47% | +21.56% |
| Paradigm Biocapital | $15.1M | 4.73% | 0.00% |
| Andera Partners | $13.7M | 4.30% | +99.83% |
| ADAR1 | $13.6M | 4.27% | +65.87% |
—
Largest filed tie
—
News
Expected move
No implied move.